https://www.selleckchem.com/products/blz945.html
Oncotype Dx® (ODX) is the most used prognostic and predictive assay for ER+breast cancer (BCa) and is categorized into low ( 18), intermediate (18 to 3, or high (≥31) risk of recurrence. Prosigna® is a prognostic signature to estimate distant recurrence-free survival for stage I/II, ER+ cancer in postmenopausal women treated with adjuvant therapy. The goal of the study is to assess the agreement between ODX and Prosigna®. 100 previously ODX classified peri and postmenopausal, early-stage (I or II) BCa patients were retrieved and Pr
Like
Comment
Share
